
    
      This is a Phase III, multicentre, single-arm, open-label study to evaluate the long-term
      safety of 100 mg Z-338 TID in subjects with FD.

      The study comprises a screening period (up to 3 weeks), a run-in period (1 week) and an
      open-label treatment period (52 weeks). Including an additional 2-week follow-up period for
      assessment of AEs, the maximum duration of a subject's participation in the study will be 58
      weeks.
    
  